Boston, MA 10/02/2013 (wallstreetpr) – In Tuesday’s trading, Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) dropped by 12.25%. The shares opened at a price of $2.99, climbed to an intraday high of $3.04 and dipped to a close of $2.65. Approximately 12.20 million shares were traded on Tuesday while an average volume of 2.52 million shares were traded over a 30 day period. The 52-week low of the company’s shares is $2.62 and its 52-week high is $11.36. The company has a market capitalization of $256.10 million.
About the company
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) was incorporated on 17 August 1998. It is a bio-pharma company that focuses on discovering, developing and commercializing of treatments that are used for infectious diseases. Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) is involved in developing antivirals that are used to treat patients suffering from chronic hepatitis C infection.
It also develops antibacterials that are used to treat various resistant-bacterial infections. It focuses on developing its 4 drug candidates that are used in HCV treatment: 1) ACH-1625, which is a NS3 protease-inhibitor, 2) ACH-2684, which is a NS3 protease-inhibitor, 3) ACH-2928, a NS5A-inhibitor, and 4) ACH-3102, a NS5A-inhibitor.
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) is also evaluating ACH-1625. This is a protease-inhibitor for the treatment of chronic hepatitis C and is in a phase IIA clinical-trial to assess its safety, tolerability, pharmacokinetic-properties and efficacy in HCV-infected subjects.
Other drug candidates
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) has established numerous other product candidates in the pipeline. It is seeking appropriate collaborative-partners for these products. It does not have required resources for ACH-2881 and ACH-702 for drug-resistant bacterial infections and the drug called elvucitabine for HIV infection.
Competitors
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) competes with Merck, Roche, Celgene, Vertex, Pfizer, Abbott, Boehringer Ingelheim, Astra-Zeneca, Novartis, Human Genome Sciences. Its other competitors are Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Enanta, Presidio, Johnson & Johnson, Medivir and Valeant.
